Media stories about Caladrius Biosciences (NASDAQ:CLBS) have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Caladrius Biosciences earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.5628442004924 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Caladrius Biosciences (NASDAQ CLBS) opened at $3.92 on Friday. Caladrius Biosciences has a 52 week low of $2.63 and a 52 week high of $7.79. The company has a market capitalization of $37.32, a P/E ratio of -1.89 and a beta of 1.59.
Caladrius Biosciences (NASDAQ:CLBS) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.38) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.79) by $0.41. analysts expect that Caladrius Biosciences will post -2.33 EPS for the current year.
CLBS has been the subject of several analyst reports. Zacks Investment Research raised Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a report on Tuesday, September 26th. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Caladrius Biosciences in a research note on Friday, November 10th.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/12/caladrius-biosciences-clbs-earns-daily-media-sentiment-rating-of-0-13.html.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.